Nirmatrelvir / Ritonavir: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), G-BA (Germany) and HAS (France), among others, recommended or restricted nirmatrelvir / ritonavir, while AOTMIT (Poland) did not recommend it.
The record spans 4.2 years, opening at HAS (France) on 6 Apr 2022 and running to 4 Jun 2026.
No assessment is on file from PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 10 of 15 records date from 2023 or later.
1 of these 15 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess nirmatrelvir / ritonavir, on 6 Apr 2022; HIRA (South Korea) did not open a file until 29 Aug 2024 — a moderate spread of 2.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
3 of the 11 agencies here assessed nirmatrelvir / ritonavir more than once, ZIN (Netherlands) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for nirmatrelvir / ritonavir.
The full ledger for nirmatrelvir / ritonavir reads 6 recommended, 4 advice, 1 no benefit and 1 deferred to NICE, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 18 Sep 2024 | Advies - blijf nirmatrelvir/ritonavir (Paxlovid®) vergoeden voor de behandeling van COVID-19 | advice published | source |
| HIRA (South Korea) | 29 Aug 2024 | 중증으로 진행될 위험이 높은 성인에서 경증 및 중등증 코로나바이러스 감염증 -19 | reimbursement appropriate | source |
| AWMSG (Wales) | 13 Mar 2024 | Treatment of COVID 19 in adults who do not require supplemental oxygen and who are at increased risk for progression to … | excluded, NICE appraised | source |
| CONITEC (Brazil) | 7 Mar 2024 | Tratamento da Covid19 em adultos que não requerem oxigênio suplementar e que apresentam risco aumentado de progressão pa… | incorporated into SUS | source |
| AOTMIT (Poland) | 11 Jul 2023 | Paxlovid reimbursement recommendation | not recommended | source |
10 further decisions for nirmatrelvir / ritonavir, across 8 agencies, are not shown here. They include the most recent record on file, 4 Jun 2026 from G-BA (Germany); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 15 decisions for nirmatrelvir / ritonavir from 11 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.